|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Multidisciplinary Care Teams to Optimize Care of Patients with Bone Metastatic CRPC |
Tanya Dorff, MD
Tanya Dorff and Alicia Morgans discuss the importance of multidisciplinary care teams for patients with bone metastatic castration-resistant prostate cancer (mCRPC). |
|
|
|
|
|
|
|
|
|
|
| Optimal Sequencing - Should It Include Radium Given Lutetium? |
Joe M. O'Sullivan, MD, FRCPI, FFRRSCI, FRCR
Joe O’Sullivan joins Alicia Morgans in a conversation about metastatic castration-resistant prostate cancer and the recent approval of lutetium-PSMA-617. As a radiation oncologist, Dr. O’Sullivan shares his views on effective sequencing of radium-223 and lutetium-177 for patients, especially given previous lines of treatment. |
|
|
|
|
|
|
|
|
|
|
| Treatment Sequencing with Radium-223 in Symptomatic Disease
|
Fred Saad, MD, FRCS
In this conversation, Fred Saad and Alicia Morgans discuss treatment sequencing in terms of Radium-223 when treating a minimally symptomatic patient or a maximally symptomatic patient.
|
|
|
|
|
|
|
|
|
|
|
| Identifying the Right Patients For Treatment with Radium-223 for mCRPC |
Brenda Martone, MSN, ANP-BC, AOCNP
Brenda Martone joins Alicia Morgans in a conversation on identifying appropriate patients for radium-223 (223Ra) treatment. Brenda Martone and Alicia Morgans discuss radium-223 before safely getting lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) after. |
|
|
|
|
|
|
|
|
|
|
| Lutetium-177-PSMA Therapy in Patients with Prior Radium-223: Safety and Effectiveness Outcomes in the RALU Study
|
| Kambiz Rahbar, MD
|
| Kambiz Rahbar discusses the safety and effectiveness outcomes of 177Lu-PSMA therapy in patients with prior radium-223 treatment. Incorporation of radium-223 in common therapy sequences for mCRPC is feasible, including taxane-based chemotherapy in between radium-223 and 177Lu-PSMA, without alteration of safety profile or overall survival from the start of 177Lu-PSMA.
|
|
|
|
|
|
| The Importance of Lifestyle and Prevention of Complications in Advanced Prostate Cancer: How to Take Care of the Bones?
|
| Oliver Sartor, MD
|
| Oliver Sartor discusses how we should best take care of our patient’s bones and the importance of lifestyle and prevention of complications in advanced prostate cancer. Dr. Sartor emphasized that various studies continue to indicate that bone health agents are underutilized in all settings. For example, even with the recent VISION trial publication, only 56% of patients received concomitant bone health agents, with various real-world evidence studies from multiple countries showing similar data.
|
|
|
|
|
|
|
|
|
|
|
| Alkaline Phosphatase Decline and Pain Response as Markers for OS in Patients with mCRPC Treated with Radium-223 in the REASSURE Study |
| Joe O'Sullivan, MD, FRCPI, FFRRSCI, FRCR |
| Joe O'Sullivan discusses alkaline phosphatase (ALP) decline and pain response as markers for overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 in the REASSURE study. These results may help physicians and patients monitor markers of pain and ALP decline during radium-223 treatment that may be associated with survival, and therefore may help to support clinical decisions. |
|
|
|
|
|
| Updated Biomarker Results From a Phase 1/2 Study of Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE) |
| Rana R. McKay MD |
| Rana McKay presented results from the COMRADE trial assessing the combination of olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases. Each of these agents is approved for patients with mCRPC. However, preclinical models have suggested potential synergy as PARP inhibitors have shown efficacy as radiosensitizing agents which may promote the efficacy of radium-223, an α-emitting radioisotope that induces DNA double-strand breaks leading to cell death. |
|
|
|
|
|
 |
